We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 18, 2021

Long-Term Outcomes With Frontline Nilotinib vs Imatinib in Newly Diagnosed CML in Chronic Phase

Leukemia

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia
Long-Term Outcomes With Frontline Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 10-Year Analysis
Leukemia 2021 Jan 07;[EPub Ahead of Print], HM Kantarjian, TP Hughes, RA Larson, DW Kim, S Issaragrisil, P le Coutre, G Etienne, C Boquimpani, R Pasquini, RE Clark, V Dubruille, IW Flinn, S Kyrcz-Krzemien, E Medras, M Zanichelli, I Bendit, S Cacciatore, K Titorenko, P Aimone, G Saglio, A Hochhaus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading